A single-inhaler triple therapy improved lung function in adults and adolescents with inadequately controlled asthma and was ...

AstraZeneca stock bounded into a buy zone Thursday after sales of its cancer drugs beat Wall Street's expectations by about 5 ...

Iconovo AB (publ), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, has today appointed Anders Månsson as interim CEO of Iconovo AB. The Board ...

To keep up with COPD research and care developments, the 2026 Global Initiative for Chronic Obstructive Lung Disease report ...

Early detection and innovative biologic treatment can prevent hospitalizations, improve quality of life, and extend the ...

Measuring lung function earlier in life would help identify people at risk of developing chronic obstructive pulmonary disease (COPD) and allow for more timely interventions, according to a new study ...

Men and women with chronic obstructive pulmonary disease (COPD), bronchiectasis, and nontuberculous mycobacterial (NTM) lung ...

In its second pipeline-expanding deal in the space of 24 hours, GSK has licensed rights to a drug for chronic obstructive pulmonary disease (COPD) from US biotech Empirico for $85 million upfront. The ...

Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...

TAIPEI (Taiwan News) — Extreme weather can affect people with chronic obstructive pulmonary disease, a long-term lung condition, a recent study from Taiwan shows. The research, published in Science of ...

Qureight’s Vascul8 model has been validated in a peer-reviewed study marking a significant advance in the treatment of pulmonary vascular disorders. The AI-powered imaging platform demonstrated its ...